Evan Zisholtz

Evan Zisholtz's work experience includes serving as the Vice President of Corporate Development at Immunai since July 2022. Prior to that, they worked at Lonza from 2015 to 2022, holding various roles such as Senior Director of M&A and Corporate Development, member of the Cell and Gene Therapy Leadership Team, and Associate General Counsel. Evan also served as a Board Member at Octane Biotech from November 2018 to July 2022. Before joining Lonza, Evan worked as an Associate at Sheppard Mullin Richter & Hampton LLP from February 2014 to July 2015, and at Paul, Weiss, Rifkind, Wharton & Garrison LLP from September 2009 to February 2014. Additionally, they were a Secondee at Apollo Capital Management from June 2012 to December 2012.

Evan Zisholtz obtained their J.D. degree from New York University School of Law between 2006 and 2009.